ATYR — aTyr Pharma, Inc.

Summary of aTyr Pharma Q4 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of year-end 2024, aTyr reported $75.1 million in cash and equivalents. Following the quarter, the company raised approximately $18.8 million through an at-the-market offering.
• Revenue: Collaboration and license revenue from the Kyorin agreement totaled $0.2 million for the year, with potential future milestone payments of up to $155 million.
• Expenses: Research and development expenses were $54.4 million, primarily driven by clinical trial costs for the EFZO-FIT and EFZO-CONNECT studies. General and administrative expenses amounted to $13.8 million.
• Cash Runway: The company expects its cash runway to support operations for at least one year following the Phase 3 EFZO-FIT readout.

2. Strategic Updates and Business Highlights

• Clinical Progress: Enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis was completed, with top-line data expected in Q3 2025. The study includes 268 patients across 85 centers in 9 countries.
• Expanded Access Program (EAP): Following the trial, patients can transition to an EAP for continued treatment with efzofitimod, reflecting strong interest from investigators and patients.
• FDA Engagement: A Type C meeting with the FDA clarified the statistical analysis plan, shifting the primary endpoint for steroid reduction to an absolute change from baseline, which is expected to simplify data analysis.
• Market Insights: New epidemiological data indicates a larger patient population for pulmonary sarcoidosis, suggesting a significant market opportunity for efzofitimod, estimated at $2 billion to $5 billion globally.

3. Forward Guidance and Outlook

• Upcoming Milestones: The company anticipates releasing interim data from the EFZO-CONNECT study in Q2 2025, focusing on skin assessments in scleroderma patients.
• Commercial Readiness: aTyr is preparing for potential commercialization of efzofitimod, having appointed a new board member with experience in launching pharmaceuticals for rare diseases.
• Long-term Strategy: The company is exploring additional indications for efzofitimod and advancing other pipeline candidates (ATYR0101 and ATYR0750) targeting fibrosis in various organs.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The shift in the statistical analysis plan could introduce uncertainties in trial outcomes, though management remains confident in the study's powering.
• Market Competition: While the company sees a significant opportunity in sarcoidosis, it faces competition from established therapies and potential new entrants in the market.
• EAP Limitations: Not all patients from the trial may transition to the EAP due to regulatory restrictions in certain countries, which could limit the data available for future analyses.

5. Notable Q&A Insights

• Statistical Analysis Change: Management emphasized that the change to measure absolute steroid reduction simplifies the analysis and maintains a high statistical power (>90%).
• EAP Participation: Interest in the EAP is high, but specific participation rates are difficult to quantify due to varying regulatory environments across countries.
• Durability of Response: Management highlighted the importance of evaluating the long-term effects of efzofitimod, particularly regarding steroid tapering and potential remission in patients.
• Skin Assessment in SSc: The interim data from the EFZO-CONNECT study will focus on skin pathology, which could open new therapeutic avenues for efzofitimod beyond lung indications.

Overall, aTyr Pharma is positioned for significant developments in 2025, with a strong focus on advancing its lead candidate efzofitimod while navigating regulatory and competitive challenges.